[VoiceOps] Phase III clinical trials of Kamailio DMQ

Thu Apr 1 15:38:56 EDT 2021

Right?  Where do they find all these blind doctors?

On Thu, Apr 1, 2021 at 12:37 PM Mary Lou Carey <marylou at backuptelecom.com>
wrote:

> Maybe they should open their eyes instead of doing a double-blind study!
> LOL!
>
> MARY LOU CAREY
> BackUP Telecom Consulting
> Office: 615-791-9969
> Cell: 615-796-1111
>
> On 2021-04-01 02:27 PM, Hiers, David wrote:
> > No AI here...  This is classic, small-batch, hand-crafted, free-range,
> > organic, gluten-free content.
> >
> >
> > David
> >
> >
> > -----Original Message-----
> > From: VoiceOps <voiceops-bounces at voiceops.org> On Behalf Of Alex
> > Balashov
> > Sent: Thursday, April 1, 2021 12:18 PM
> > To: Brandon Svec <bsvec at teamonesolutions.com>
> > Cc: voiceops at voiceops.org
> > Subject: Re: [VoiceOps] Phase III clinical trials of Kamailio DMQ
> >
> > Let me make sure I understand your question correctly: it is your
> > belief or conjecture that this press release was automatically
> > generated by a machine learning system?
> >
> > —
> > Sent from mobile, with due apologies for brevity and errors.
> >
> >> On Apr 1, 2021, at 3:10 PM, Brandon Svec <bsvec at teamonesolutions.com>
> >> wrote:
> >>
> >> GPT-3? Happy April Fools Day.
> >>
> >> Brandon
> >>
> >>> On Mar 31, 2021, at 9:47 PM, Alex Balashov
> >>> <abalashov at evaristesys.com> wrote:
> >>>
> >>> For immediate release:
> >>>
> >>> GAINESVILLE, Florida (1 April 2021)--Evariste Systems, in partnership
> >>> with Posner | Palner Pharmaceuticals, are pleased to announce the
> >>> eagerly anticipated start of Phase III clinical trials of Kamailio
> >>> DMQ module replication.
> >>>
> >>> In this stage of the investigation of the promising replication
> >>> scheme, which was developed in record time, DMQ will be tested in a
> >>> rigourous, double-blind, controlled CI/CD process for large-scale
> >>> efficacy and continually monitored for safety in shorter and longer
> >>> terms.
> >>>
> >>> The now-concluded second phase established basic safety and Phase 2b
> >>> entailed a dose-finding study for the optimal number of batched
> >>> `dmq_usrloc` contacts per kilogram of cloud computing resource.
> >>>
> >>> The main cohort of the main sequence of the Phase III trial will
> >>> enroll 380 randomly selected, statistically representative Floridian
> >>> SIP registrars and
> >>> 5700 SIP dialogs, also in the state of Florida. When asked about the
> >>> disparity in the number of registrars versus dialogs, Alex Balashov
> >>> of Evariste said, "It is reflective of the small number of SIP
> >>> registrars in Florida; not to be indelicate, but consider the median
> >>> age of the population."
> >>>
> >>> As previously remarked upon in proceedings of the World SIP
> >>> Organisation (WSO), the choice of Florida as a venue attracted some
> >>> questions. We asked Fred Posner of Posner | Palner about the clinical
> >>> background informing this choice of replication study cohort:
> >>>
> >>> "Florida is a good place to find eventual consistency failures; the
> >>> open climate and reluctance to accept traditional data integrity
> >>> science would have sealed the deal, but when people started to drink
> >>> bleach here, I saw an opportunity."
> >>>
> >>> Evariste and Posner | Palner are aiming for a US Food & Drug
> >>> Administration EUA (Emergency Use Authorisation) for DMQ replication
> >>> as a prophylactic data redundancy and failover measure to ward off
> >>> the development of moderate to severe viral Sonus Haemorrhagic Fever
> >>> symptoms.
> >>>
> >>> Phase II studies have painted a promising a picture of the DMQ
> >>> architecture's ability to reduce moderate to severe symptoms and
> >>> associated 28-day mortality by more than 90%, albeit over a small
> >>> sample size and in enterprise patients with known pre-existing
> >>> comorbidities such as Session Border Controller and BroadSoft
> >>> Multi-System Inflammatory Syndrome.  Phase III trials seek to bolster
> >>> quantums of broader efficacy, including efficacy for localised
> >>> outbreaks of small to medium business softswitch.
> >>>
> >>> Of the control group, Balashov said, "They will receive a standard
> >>> pipe-to-/dev/null placebo protocol, but with identical '200 OK'
> >>> confirmation messages. We proudly developed this approach in early
> >>> 2020 in consultation with the highest levels of the Trump
> >>> presidential administration; it is called TENP, or 'The Emperor's New
> >>> Potion.' It is a successor to that administration's previous approved
> >>> placebo protocol, SHTI - Small Hands, Tremendous Initiatives."
> >>>
> >>> Despite speculative autism and packet fragmentation claims by Florida
> >>> Governor Ron DeSantis, Balashov was quick to provide reassurance
> >>> about side effects from DMQ in the Phase III trial.
> >>>
> >>> "The incidence of severe allergies to plain-text UDP was within
> >>> standard deviation over the mean for all insecure replication, and
> >>> there's support for other transports on the way. Anyway, we have a
> >>> robust adverse effects reporting system in our issue tracker and
> >>> solid surveillance. Don't let partisan politics dissuade you from
> >>> allowing request lines with the KDMQ method."
> >>>
> >>> Other industry sources have reported that DMQ is not the only
> >>> replication investigation undertaken by Evariste and Posner | Palner,
> >>> although it is the only prophylactic suitable for the early infection
> >>> development and inflammatory phases of a broad class of SBC-complex
> >>> syndromes typically afflicting service providers. A recent IETF
> >>> preprint by the same authors has shown high-quality preliminary data
> >>> suggesting statistically significant improvement in morbidity
> >>> outcomes from Perimeta and Nokia via a later-stage therapeutic
> >>> intervention with a monoclonal, monorepo Github cocktail administered
> >>> intravenously.
> >>>
> >>>
> >>> --
> >>> Alex Balashov | Principal | Evariste Systems LLC
> >>>
> >>> Tel: +1-706-510-6800 / +1-800-250-5920 (toll-free)
> >>> Web: http://www.evaristesys.com/, http://www.csrpswitch.com/
> >>> _______________________________________________
> >>> VoiceOps mailing list
> >>> VoiceOps at voiceops.org
> >>> https://puck.nether.net/mailman/listinfo/voiceops
> > _______________________________________________
> > VoiceOps mailing list
> > VoiceOps at voiceops.org
> > https://puck.nether.net/mailman/listinfo/voiceops
> >
> > ----------------------------------------------------------------------
> > This message and any attachments are intended only for the use of the
> > addressee and may contain information that is privileged and
> > confidential. If the reader of the message is not the intended
> > recipient or an authorized representative of the intended recipient,
> > you are hereby notified that any dissemination of this communication
> > is strictly prohibited. If you have received this communication in
> > error, notify the sender immediately by return email and delete the
> > message and any attachments from your system.
> > _______________________________________________
> > VoiceOps mailing list
> > VoiceOps at voiceops.org
> > https://puck.nether.net/mailman/listinfo/voiceops
> _______________________________________________
> VoiceOps mailing list
> VoiceOps at voiceops.org
> https://puck.nether.net/mailman/listinfo/voiceops
>
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <https://puck.nether.net/pipermail/voiceops/attachments/20210401/27335e1b/attachment.htm>